Rubius Therapeutics (RUBY) Reports Q3 Loss of $0.59
Tweet
Share
E-mailGet Alerts RUBY Hot Sheet
Join SI Premium – FREE
Rubius Therapeutics (NASDAQ: RUBY) reported Q3 EPS of ($0.59), versus ($0.42) reported last year.
For earnings history and earnings-related data on Rubius Therapeutics (RUBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Royal Unibrew reports higher interim first-half profit as margins improve
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
